A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ: QNTM) (Profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at protecting and potentially repairing the myelin sheath itself. The clearance sets the stage for what would be the first time in history that a drug candidate built on this specific mechanism is tested in people living with the MS disease, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. This momentum places Quantum BioPharma solidly in a group of leading companies focused on the treatment of serious diseases and areas of significant unmet medical need across vaccines, ophthalmology and neurological disease, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). Research indicates that MS affects an estimated one million people in the United States and approximately 2.9 million people worldwide. The FDA’s clearance of Quantum BioPharma’s Investigational New Drug (“IND”) application marks a genuinely rare moment in MS research. In addition to the upcoming phase 2 drug trial, Quantum BioPharma has spent more than a year building a parallel research partnership with scientists at Massachusetts General Hospital (“MGH”) and Harvard Medical School. Lucid-MS, also known by its research designation Lucid-21-302, is built around a different theory of how to target MS progression. Clinical milestones matter to patients, but they also move markets, and Quantum BioPharma has recently drawn fresh attention from Wall Street analysts. For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile. https://ibn.fm/CzNQ5   To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com